Expanding prefillable glass syringe output: SCHOTT Pharma opens
state-of-the-art production facility in Lukácsháza, Hungary

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Expansion
Expanding prefillable glass syringe output: SCHOTT Pharma opens
state-of-the-art production facility in Lukácsháza, Hungary

14.06.2024 / 12:58 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Expanding prefillable glass syringe output: SCHOTT Pharma opens
state-of-the-art production facility in Lukácsháza, Hungary

June 11, 2024, Lukácsháza, Hungary

  * After EUR 76 million (HUF 28,044 billion) investment and 1.5 years of
    construction, SCHOTT Pharma opens its newest production facility in
    Lukácsháza, Hungary

  * Expanding production capacity will support pharma megatrends and market
    growth for prefillable syringes made of specialty glass

  * With financial support from the local government, the facility brings
    over 120 new jobs to the area

After breaking ground in October 2022 and fresh of its IPO in September
2023, SCHOTT Pharma opened the doors to an entirely new production facility
for high-quality prefillable glass syringes in Hungary. Supported by a EUR 9
million (HUF 3,321 billion) investment from the local government, SCHOTT
Pharma's double-digit million Euro investment is realized today with the
opening of a facility that creates over 120 jobs. With this move, SCHOTT
Pharma is expanding its global capacities for strategically important
high-value solutions that address key pharma trends. At the same time, the
company is strengthening its competitiveness in Europe and the supply
security for major pharmaceutical companies and contract manufacturing
organizations. To supply the fast and dynamically growing market, SCHOTT
Pharma plans to further invest a multi-million Euro amount in Hungary in
prefillable syringes in the next years.

"With an increasing number of drugs being stored in prefillable glass
syringes - from GLP-1 drugs to critical vaccines and innovative biologics,
the manufacturing beginning at this site today will continue to support
major trends in the pharma industry," says Andreas Reisse, CEO of SCHOTT
Pharma.

As evidenced by their growing demand in the healthcare industry, these
high-quality prefillable glass syringes not only offer a stable, long-term
storage solution for drugs, but also a safe and convenient delivery system
for patients and clinicians.

Drug containment and delivery play a critical role in medication protocols.
Traditionally, a newly developed drug is launched in vials, with healthcare
providers using disposable syringes for extraction and administration.
Today, more and more pharmaceutical companies are moving towards filling
medicines directly into prefillable syringes to enable storage and
administration in one, streamlining the injection process for healthcare
professionals and improving the accuracy of dosing for patients.

SCHOTT Pharma's Hungarian site, that was inaugurated in Lukácsháza today,
builds on the company's existing foundation and pharmaceutical production
skillset in the area, which already plays an important role in supplying the
global industry with drug containment systems today. Following the high-end
processes and advanced quality assurance found in SCHOTT Pharma's global
production network in 14 countries, the facility is equipped with
state-of-the-art machinery. The new site is the second site where the
company manufactures glass syringes, in addition to the site in St. Gallen
in Switzerland.


More information on prefillable glass syringes:
https://www.schott-pharma.com/en/products/syringes/syriq

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded
in science to ensure that medications are safe and easy to use for people
around the world. The portfolio comprises drug containment solutions and
delivery systems for injectable drugs ranging from prefillable glass and
polymer syringes to cartridges, vials, and ampoules. Every day, a team of
over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute
to global healthcare. The company is represented in all main pharmaceutical
hubs with 16 manufacturing sites in Europe, North and South America, and
Asia. With over 1,000 patents and technologies developed in-house and a
state-of-the-art R&D center in Switzerland, the company is focused on
developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is
headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange
as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl
Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to
sustainable development for society and the environment and has the
strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma
has over 1,800 customers including the top 30 leading pharma manufacturers
for injectable drugs and generated revenue of EUR 899 million in the fiscal
year 2023.

Press contact:

Lea Kaiser
Communications Manager
+49 (0)6131/66-4073
Lea.Kaiser@schott.com

Jasko Terzic, CFA
Senior Manager Investor Relations
IR.Pharma@schott.com


---------------------------------------------------------------------------

14.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        SCHOTT Pharma AG & Co. KGaA
                   Hattenbergstraße 10
                   55122 Mainz
                   Germany
   ISIN:           DE000A3ENQ51
   WKN:            A3ENQ5
   Indices:        SDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate
                   Exchange; Vienna Stock Exchange
   EQS News ID:    1925735

End of News EQS News Service
---------------------------------------------------------------------------

1925735 14.06.2024 CET/CEST